JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

Strona główna・Stock List・uniQure NV

uniQure NV

Closed

17.72 1.55

Buy Sell

Overview

Share price change

24h

Current

Min

17.28

Max

17.91

Key metrics
By Trading Economics
Income	43M -37M
Sales	1.9M 5.6M
Profit margin	-666.056
Employees	221
EBITDA	2.4M -49M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+84.01% upside

Dividends
By Dow Jones
Next Earnings	8 maj 2026

Market Stats
By TradingEconomics
Market Cap	-396M 1.1B
Previous open	16.17
Previous close	17.72

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

10.05 / 14.75 Support & Resistance

uniQure NV Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

2 mar 2026, 13:13 UTC

Major Market Movers

UniQure Down in Premarket as FDA Says Huntington's Gene-Therapy Data Falls Short

9 sty 2026, 15:14 UTC

Major Market Movers

UniQure Climbs on Scheduling FDA Meeting for Huntington's Disease Treatment

3 lis 2025, 13:34 UTC

Major Market Movers

UniQure Shares Sink After Negative FDA Response to Huntington's Disease Treatment

24 wrz 2025, 18:51 UTC

Earnings

These Stocks Are Moving the Most Today: Alibaba, Micron, Lithium Americas, Freeport-McMoRan, uniQure, and More -- Barrons.com

Peer Comparison

Price change

uniQure NV Forecast

Price Target

By TipRanks

84.01% upside

12 Months Forecast

Average 32.11 USD 84.01%

High 70 USD

Low 9 USD

Based on 12 Wall Street analysts offering 12 month price targets foruniQure NV - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

12 ratings

Buy

Hold

Sell

Based on 12 analysts giving stock ratings to uniQure NV - Dist in the past 3 months.

Technical Score

By Trading Central

10.05 / 14.75Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About uniQure NV

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.